Hoher Blutdruck bei Frauen – geschlechtsspezifische Besonderheiten

Die arterielle Hypertonie, insbesondere ein erhöhter systolischer Blutdruck, ist ebenso wie bei Männern auch bei Frauen der häufigste Risikofaktor für kardio- und zerebrovaskuläre Morbidität und Mortalität. Die Blutdruckregulation und die Entwicklung einer manifesten Hypertonie unterscheiden sich geschlechtsspezifisch. Zur Frage, ob die aktuellen Normwerte gleichermaßen für Männer und Frauen gelten können und zur Frage einer unterschiedlichen Wirkung und Dosierung der Antihypertensiva bei Frauen gibt es noch zu wenige Daten.

Abstract

Arterial hypertension, particularly elevated systolic blood pressure, is the most common risk factor for cardio- and cerebrovascular morbidity and mortality in women as it is in men. Blood pressure regulation and the development of sustained hypertension differ by sex. There are still few data on the question of whether the current normal values can apply equally to men and women and on the question of a different effect and dosage of antihypertensive drugs in women.

Kernaussagen

• Die Blutdruckregulation und die Entwicklung einer manifesten Hypertonie unterscheiden sich geschlechtsspezifisch.

• Bei Frauen werden sie u.a. beeinflusst von den weiblichen Geschlechtshormonen, der besonderen Gefäßarchitektur und -funktion und von hypertensiven Schwangerschaftserkrankungen.

• Die Prävalenz der arteriellen Hypertonie und das Risiko sind bei Frauen stärker als bei Männern abhängig vom Alter.

• Die Blutdruckwerte sind bei Frauen in der Jugend und im jungen Erwachsenenalter niedriger als bei Männern.

• Im mittleren Lebensalter steigt der Blutdruck dann stärker an als bei Männern und das Risiko erhöht sich bereits bei niedrigeren Werten.

• In der Wirkung der unterschiedlichen Antihypertensiva zeigen sich außer bei den Kalziumantagonisten keine wesentlichen Unterschiede bei Männern und Frauen, wohl aber in den Nebenwirkungen.

Schlüsselwörter

Bluthochdruck - arterielle Hypertonie - kardiovaskuläres Risiko - Antihypertensiva - Geschlechterunterschiede

Keywords

high blood pressure - arterial hypertension - cardiovascular risk - antihypertensive drugs - gender differences

Publication History

Article published online:
24 April 2023

• Literatur

• 1 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811
• 2 Philbois SV, Facioli TP, Gastaldi AC. et al. Important differences between hypertensive middle-aged women and men in cardiovascular autonomic control-a critical appraisal. Biol Sex Differ 2021; 12: 11
• 3 Engelen L, Ferreira I, Stehouwer CD. et al. Reference values for arterial measurements C. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J 2013; 34: 2368-2380
• 4 Holder SM, Bruno RM, Shkredova DA. et al. Reference intervals for brachial artery flow-mediated dilation and the relation with cardiovascular risk factors. Hypertension 2021; 77: 1469-1480
• 5 McEniery CM Y, Hall IR, Qasem A. et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the anglo- cardiff collaborative trial (ACCT). J Am Coll Cardiol 2005; 46: 1753-176O
• 6 Coutinho T, Borlaug BA, Pellikka PA. et al. Sex differences in arterial stiffness and in ventricular-arterial interactions. J Am Coll Cardiol 2013; 61: 96-103
• 7 Bruno RM, Grassi G, Seravalle G. et al. Age- and sex- specific reference values for Media/lumen ratio in small arteries and relationship with risk factors. Hypertension 2018; 71: 1193-1200
• 8 Hout MJ, Dekkers IA, Westenberg JJ. et al. Normal and reference values for cardiovascular magnetic resonance-based pulse wave velocity in the middle-aged general population. J Cardiovasc Magn Reson 2021; 23: 46
• 9 Ji H, Kim A, Ebinger J. et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiol 2020; 5: 255-262
• 10 Meisinger C, Heier M, Völzke H. et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24: 293-299
• 11 Diederichs C, Neuhauser H. et al. Regional variations in hypertension prevalence and management in Germany. J Hypertens 2014; 32: 1405-1414
• 12 Neuhauser H, Kuhnert R, Born S. 12-Monats-Prävalenz von Bluthochdruck in Deutschland. J Health Monit 2017; 2
• 13 Atasoy S, Middeke M, Johar H. et al. Risk factor burden and 25-year cardiovascular disease mortality risk of isolated systolic hypertension in young adults: findings from the prospective MONICA/KORA study. J Hum Hyp 2022; 36: 1059-1065
• 14 Middeke M. Isolierte systolische Hypertonie (ISH) – Alt gegen Jung. Aktuel Kardiol 2019; 8: 354-361
• 15 Saladini F, Fania C, Mos L. et al. Office Pulse Pressure is a Predictor of favorable outcome in young- to middle-aged subjects with stage 1 hypertension. Hypertension 2017; 70: 537-542
• 16 Tan LE, Llano A, Aman A. et al. A18709 Mendelian Randomization study of causal relationship of height on blood pressure and arterial stiffness. J Hypertens 2018; 36: e91-e92
• 17 Ji H, Niiranen TJ, Ryder F. et al. Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. Circulation 2021; 143: 761-763
• 18 Brandts L and Piet A van den Brandt. Body size, non-occupational physical activity and the chance of reaching longevity in men and women: findings from the Netherlands Cohort Study. J Epidemiol Community Health 2019; 73: 239-249
• 19 Middeke M. Je größer, umso länger?. Dtsch Med Wochenschr 2021; 146: 1619-1623
• 20 Middeke M. Zentraler aortaler Blutdruck: Bedeutender Parameter für Diagnostik und Therapie. Dtsch Med Wochenschr 2017; 142: 1430-1436
• 21 Middeke M, Nasemann J, Luft FC. Little Old Ladies’Eye. Artery Research 2019; 25: 77-80
• 22 Tita AT, Szychowski JM, Boggess K. et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386: 1781-1792
• 23 Mulder EG, Ghossein-Doha C, Cauffman E. et al. Preventing Recurrent Preeclampsia by Tailored Treatment of Nonphysiologic Hemodynamic Adjustment to Pregnancy. Hypertension 2021; 77: 2045-2053
• 24 McLaughlin K, Snelgrove JW, Sienas LE. et al. Phenotype-Directed Management of Hypertension in Pregnancy. J Am Heart Assoc 2022; 11: e023694
• 25 Kjeldsen SE, Hedner T, Syvertsen JO. et al. Influence of age, sex and blood pressure on the principal endpoints of the nordic diltiazem (NORDIL) study. J Hypertens 2002; 20: 1231-1237
• 26 Lewis CE, Grandits A, Flack J. et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the treatment of mild hypertension study. Arch Intern Med 1996; 156: 377-385
• 27 Os I, Franco V, Kjeldsen SE. et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the losartan intervention for endpoint reduction in hypertension study. Hypertension 2008; 51: 1103-1108
• 28 Kjeldsen SE, Warnold I, Hansson L. et al. Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study. J Gend Specif Med 2000; 3: 35-38
• 29 Wing LM, Reid CM, Ryan P. et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592
• 30 Zanchetti A, Julius S, Kjeldsen S. et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-2168
• 31 Gerdts E, Sudano I, Brouwers S. et al. Sex differences in arterial hypertension. Euro Heart J 2022; 43: 4777-4788
• 32 Turnbull F, Woodward M, Neal B. et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669-2680
• 33 Reboussin DM, Allen NB, Griswold ME. et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2018; 138: e595-e616
• 34 Tamargo J, Rosano G, Walther T. et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother 2017; 3: 163-182
• 35 Kajiwara A, Saruwatari J, Kita A. et al. Younger females are at greater risk of vasodilation-related adverse symptoms caused by dihydropyridine calcium channel blockers: results of a study of 11,918 Japanese patients. Clin Drug Investig 2014; 34: 431-435
• 36 Os I, Bratland B, Dahlof B. et al. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens 1994; 7: 1012-1015
• 37 Kloner RA, Sowers JR, DiBona GF. et al. Sex- and age-related antihypertensive effects of amlodipine. The amlodipine cardiovascular community trial study group. Am J Cardiol 1996; 77: 713-722
• 38 SPRINT Research Group, Wright Jr JT, Williamson JD. et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-2116
• 39 Williamson JD, Supiano MA, Applegate WB. et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: A randomized clinical trial. JAMA 2016; 315: 2673-2682
• 40 Foy CG, Lovato LC, Vitolins MZ. et al. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the systolic blood pressure intervention trial. J Hypertens 2018; 36: 904-915
• 41 Ochoa-Jimenez R, Viquez-Beita K, Daluwatte C. et al. Sex differences of patients with systemic hypertension (from the analysis of the systolic blood pressure intervention trial [SPRINT]). Am J Cardiol 2018; 122: 985-993